Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The Transcription Repressor Gfi1 Directly Interacts With and Is Phosphorylated By Aurora A Kinase, Which Abrogates Myeloma-Induced Gfi1 Repression Of The Runx2 Promoter In Pre-Osteoblasts

Jixin Ding, PhD, Fengming Wang, PhD, ShunQian Jin, PhD, Judy Anderson, Deborah L. Galson, Ph.D., G. David Roodman, M.D., Ph.D.

Blood (2013) 122 (21): 1844.

https://doi.org/10.1182/blood.V122.21.1844.1844

Published: 2013

Journal Articles

The Transcription Repressor Gfi1 Directly Interacts With and Is Phosphorylated By Aurora A Kinase, Which Abrogates Myeloma-Induced Gfi1 Repression Of The Runx2 Promoter In Pre-Osteoblasts

Jixin Ding, PhD, Fengming Wang, PhD, ShunQian Jin, PhD, Judy Anderson, Deborah L. Galson, Ph.D., G. David Roodman, M.D., Ph.D.

Blood (2013) 122 (21): 1184.

https://doi.org/10.1182/blood.V122.21.1184.1184

Published: 2013

Journal Articles

Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation

Guoshuang Xu, Kai Liu, Judy Anderson, Kenneth Patrene, Suzanne Lentzsch, G. David Roodman, Hongjiao Ouyang

Blood (2012) 119 (18): 4205–4214.

https://doi.org/10.1182/blood-2011-05-353300

Published: 2012

Includes: Supplemental data

Journal Articles

Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effects of IL-3 in Myeloma,

Rebecca Silbermann, M.D., Marina Bolzoni, Paola Storti, Ph.D., Benedetta Dalla Palma, M.D., Sabrina Bonomini, Judy Anderson, G. David Roodman, M.D., Ph.D., Nicola Giuliani, M.D., Ph.D.

Blood (2011) 118 (21): 3933.

https://doi.org/10.1182/blood.V118.21.3933.3933

Published: 2011

Journal Articles

A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma

Kimberly Noonan, Luigi Marchionni, Judy Anderson, Drew Pardoll, G. David Roodman, Ivan Borrello

Blood (2010) 116 (18): 3554–3563.

https://doi.org/10.1182/blood-2010-05-283895

Published: 2010

Journal Articles

Suppression of Mesenchymal Stromal Cell (MSC) Differentiation in Multiple Myeloma (MM) Is Restricted to the Osteoblast Lineage

Flavi a Esteve, MD, Chang Sook Hong, PhD, Alissa Huston, MD, Veronica Garcia Palacios, DDS, PhD, Judy Anderson, Ken Patrene, David Roodman, MD, PhD

Blood (2008) 112 (11): 2752.

https://doi.org/10.1182/blood.V112.11.2752.2752

Published: 2008

Journal Articles

Developing In Vivo Model for Studying Mechanisms of Osteoblast Suppression in Multiple Myeloma.

Chang-Sook Hong, PhD, Alisa Huston, MD, Flavia Esteve, MD, Judy Anderson, Ken Patrene, David Roodman, MD, PhD

Blood (2007) 110 (11): 4731.

https://doi.org/10.1182/blood.V110.11.4731.4731

Published: 2007

Journal Articles

Th-17 Lymphocytes, Not Regulatory T Cells, Mediate Immune Regulation of Bone Marrow Infiltrating Lymphocytes and Induce Osteoclast Activation in Multiple Myeloma.

Kimberly A. Noonan, Judy Anderson, Stephanie Mgebroff, Paolo Serafini, David Roodman, Ivan Borrello

Blood (2007) 110 (11): 811.

https://doi.org/10.1182/blood.V110.11.811.811

Published: 2007

Journal Articles

Herpes-Simplex Thymidine Kinase Gene as a Selective Marker in Evaluating the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, BS, Ken Patrene, BS, Lily Hong, MD, Lori Ehrlich, PhD, David Roodman, MD, PhD

Blood (2006) 108 (11): 510.

https://doi.org/10.1182/blood.V108.11.510.510

Published: 2006

Journal Articles

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1

Gülsüm Anderson, Margarete Gries, Noriyoshi Kurihara, Tadashi Honjo, Judy Anderson, Vera Donnenberg, Albert Donnenberg, Irene Ghobrial, Markus Y. Mapara, David Stirling, David Roodman, Suzanne Lentzsch

Blood (2006) 107 (8): 3098–3105.

https://doi.org/10.1182/blood-2005-08-3450

Published: 2006

Includes: Supplemental data

Journal Articles

Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM).

Irene Ghobrial, MD, Ujjal Singha, PhD, Yazan Alsayed, MD, Alissa Huston, MD, Lanie Francis, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD

Blood (2005) 106 (11): 2491.

https://doi.org/10.1182/blood.V106.11.2491.2491

Published: 2005

Journal Articles

Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).

Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene Ghobrial, MD

Blood (2005) 106 (11): 2413.

https://doi.org/10.1182/blood.V106.11.2413.2413

Published: 2005

Journal Articles

Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD).

Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Alissa Huston, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 2414.

https://doi.org/10.1182/blood.V106.11.2414.2414

Published: 2005

Journal Articles

The Effect of Rapamycin, 17-AAG and the Combination on the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Lanie Francis, MD, Judy Anderson, BS, Michael Timm, BS, Noriyoshi Kurihara, PhD, Ujjal Singha, PhD, Yazan Alsayed, MD, Alissa Huston, MD, Suzanne Lentzsch, MD, PhD, G. David Roodman, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 3476.

https://doi.org/10.1182/blood.V106.11.3476.3476

Published: 2005

Journal Articles

Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.

Alissa Huston, MD, Alexey Leontovich, MD, Michael Timm, MD, Yazan Alsayed, MD, Ujjal Singha, PhD, Lanie Francis, MD, Ganwei Lu, PhD, Judy Anderson, Suzanne Lentzsch, MD, Irene Ghobrial, MD

Blood (2005) 106 (11): 3402.

https://doi.org/10.1182/blood.V106.11.3402.3402

Published: 2005

Journal Articles

Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM).

Alissa Huston, MD, Lanie Francis, MD, Yazan Alsayed, MD, Ujjal Singha, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene Ghobrial, MD

Blood (2005) 106 (11): 1592.

https://doi.org/10.1182/blood.V106.11.1592.1592

Published: 2005

Journal Articles

The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM).

Alissa Huston, MD, Ujjal Singha, PhD, Yazan Alsayed, MD, Lanie Francis, MD, Ganwei Lu, MD, Judy Anderson, Suzanne Lentzsch, MD, G. David Roodman, MD, PhD, Irene M. Ghobrial, MD

Blood (2005) 106 (11): 2509.

https://doi.org/10.1182/blood.V106.11.2509.2509

Published: 2005

NARROW

The Transcription Repressor Gfi1 Directly Interacts With and Is Phosphorylated By Aurora A Kinase, Which Abrogates Myeloma-Induced Gfi1 Repression Of The Runx2 Promoter In Pre-Osteoblasts

The Transcription Repressor Gfi1 Directly Interacts With and Is Phosphorylated By Aurora A Kinase, Which Abrogates Myeloma-Induced Gfi1 Repression Of The Runx2 Promoter In Pre-Osteoblasts

Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation

Bone Marrow Monocyte / Macrophage Derived Activin A Mediates the Osteoclastogenic Effects of IL-3 in Myeloma,

A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma

Suppression of Mesenchymal Stromal Cell (MSC) Differentiation in Multiple Myeloma (MM) Is Restricted to the Osteoblast Lineage

Developing In Vivo Model for Studying Mechanisms of Osteoblast Suppression in Multiple Myeloma.

Th-17 Lymphocytes, Not Regulatory T Cells, Mediate Immune Regulation of Bone Marrow Infiltrating Lymphocytes and Induce Osteoclast Activation in Multiple Myeloma.

Herpes-Simplex Thymidine Kinase Gene as a Selective Marker in Evaluating the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1

Molecular Mechanisms Regulating Migration and Adhesion in Response to the Chemokine SDF-1 in Multiple Myeloma (MM).

Differential Response to Proteosome Inhibition in EBV Positive and Negative Lymphoma Cell Lines: Clinical Implications in Post Transplant Lymphoproliferative Disorders (PTLD).

Combination of the mTOR Inhibitor Rapamycin with the HSP90 Inhibitor 17-AAG Has Synergistic Activity in EBV Positive Post Transplant Lymphoproliferative Disorders (PTLD).

The Effect of Rapamycin, 17-AAG and the Combination on the Bone Marrow Microenvironment in Multiple Myeloma (MM).

Proteomic Analysis Identifies Differences in Multiple Myeloma (MM) Cells Sensitive and Resistant to AKT Inhibition.

Combination of the AKT Inhibitor Perifosine with the HSP90 Inhibitor 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin (17-DMAG) Has Synergistic Activity in Multiple Myeloma (MM).

The Role of the AKT Inhibitor Perifosine in Migration and Adhesion in Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only